As an example, cetuximab, an approved anti-EGFR (targeting both wild-type EGFR and EGFRvIII [14]) monoclonal antibody (mAb), administered systemically, was well tolerated but had limited activity and failed to demonstrate benefit in the progressive high-grade glioma (HGG) patient population [11]. This evidence concerns the gene EGFR and glioma.